Stent News and Research

RSS

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.

Boston Scientific's WallFlex Fully Covered Esophageal Stent receives FDA clearance and CE Mark approval

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex® Fully Covered Esophageal Stent for the treatment of malignant esophageal strictures (obstructions) caused by tumors in patients with resectable or non-resectable esophageal cancer.

20 Nov 2009

Cardiovascular Systems commences patient enrollment in CALCIUM 360° clinical trial

Cardiovascular Systems, Inc., announces the first patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company’s 360° Clinical Series. The CALCIUM 360° study will evaluate the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI’s Diamondback 360® PAD System, a minimally invasive catheter for treating PAD anywhere in the leg.

19 Nov 2009

Medtronic introduces imaging and visualization service for endovascular specialists

Continuing to drive innovation in endovascular aortic repair (EVAR), Medtronic, Inc., today announced the introduction of an imaging and visualization service for endovascular specialists who use the company’s market-leading portfolio of stent grafts to treat aortic aneurysms. Aortic aneurysms affect more than one million people in the United States alone and can rupture with fatal consequences if left untreated.

19 Nov 2009

Updated clinical guidelines on Effient treatment for ACS patients

Effient® (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardial infarction (STEMI), or severe heart attack.

19 Nov 2009

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.

19 Nov 2009

Endologix receives IDE conditional approval from FDA

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has received Investigational Device Exemption (IDE) conditional approval from the United States Food and Drug Administration ("FDA") to begin a prospective, multicenter, randomized clinical trial for a bilateral percutaneous approach to endovascular abdominal aortic aneurysm repair (EVAR) utilizing the Company's IntuiTrak(TM) endovascular delivery system for the Powerlink® family of stent grafts.

19 Nov 2009

W. L. Gore to distribute QXMédical's Q50 Stent Graft Balloon Catheter

W. L. Gore & Associates today announced it has entered into a partnership with QXMédical, LLC, a medical device development and marketing company. As part of the agreement, Gore will distribute the Q50 Stent Graft Balloon Catheter which is designed for use with aortic stent grafts that treat abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA).

18 Nov 2009

Atrium Medical presents interim results from its COBEST clinical study at the 2009 VIVA meeting

Atrium Medical Corporation is proud to announce the release of the interim results from the COBEST clinical study. This study is to evaluate the use of bare metal stents vs. balloon expandable covered stents for the treatment of aorto-iliac occlusive disease. Prof. Patrice Mwipatayi of Royal Perth Hospital, Australia, presented interim data on the Covered versus Balloon Expandable Stent Trial known as COBEST at the 2009 VIVA (Vascular InterVentional Advances) meeting in Las Vegas.

17 Nov 2009

New, reversible antiplatelet drug not superior than irreversible one in patients undergoing PCI

A new, reversible antiplatelet drug did not demonstrate superiority over a current irreversible one in reducing the composite of death, heart attack or ischemia-related revascularization in the 48 hours after angioplasty, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

17 Nov 2009

Incidence of stroke related to coronary angioplasty remain steady over a 15-year period: Mayo Clinic study

Results of a Mayo Clinic study show the incidence of stroke or mini-stroke related to a coronary angioplasty (http://www.mayoclinic.org/heart-catheterization/types.html) remained steady over a 15-year period. Researchers say this is good news because physicians now are performing the artery-opening procedure on older patients who are sicker and need more complicated treatment.

17 Nov 2009

Platelet function tests predict heart attacks in patients pre-treated with two anti-clotting medications before coronary stenting

Three platelet function tests all identified heart patients who will have blood cells that remain sticky, increasing heart attack risk, despite being pre-treated with two anti-clotting medications before coronary stenting, researchers reported at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

New reversible blood thinner for angioplasty patients not superior over placebo

A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

New reversible oral anti-platelet medication had fewer cardiac events in heart attack patients

Acutely ill heart attack patients who received both aspirin and a new reversible oral anti-platelet medication had fewer cardiac events than patients on aspirin and the most commonly used, irreversible anti-platelet drug, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

Cappella commences evaluation of the Sideguard Coronary Sidebranch Stent & Delivery System

Cappella, Inc., a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, announced the start of Sideguard 3, an IVUS/OCT evaluation of the Sideguard® Coronary Sidebranch Stent & Delivery System. This is a European multicenter study to evaluate the vascular response to Sideguard in de novo bifurcation lesions of native coronary arteries.

16 Nov 2009

Resources to help understand stroke and carotid artery disease

The Society of Interventional Radiology offers numerous resources-including publications and the first-ever Catheter Lysis of Thromboembolic Stroke (CLOTS) course-for interventional radiologists, neuroradiologists, neurointerventionists, body interventionalists, and IR and INR fellows to aid in the understanding of stroke and carotid artery disease.

12 Nov 2009

Catheter-directed therapy: First-line treatment option for massive pulmonary embolism

Catheter-directed therapy or catheter-directed thrombolysis-an interventional radiology treatment that uses targeted image-guided drug delivery with specially designed catheters to dissolve dangerous blood clots in the lungs-saves lives and should be considered a first-line treatment option for massive pulmonary embolism, note researchers in the November Journal of Vascular and Interventional Radiology.

12 Nov 2009

GORE TAG Thoracic Endoprosthesis receives European CE Mark approval

W.L. Gore & Associates (Gore) today announced that it has received European CE Mark approval for the next generation GORE TAG® Thoracic Endoprosthesis. The device is available in an expanded portfolio of sizes to meet a broad range of patient needs and was engineered to treat multiple etiologies including thoracic aortic aneurysms (TAAs), traumatic aortic transections and thoracic aortic dissections.

11 Nov 2009

FDA issues marketing approval for Onset Medical's SoloPath TransFemoral Endovascular Access Catheter

Onset Medical Corporation announced today the Company has received U.S. FDA 510(k) marketing clearance for the Company’s SoloPath™ TransFemoral Endovascular Access Catheter.

10 Nov 2009

Prescient Medical to showcase its vProtect Luminal Shield and the vPredict Optical Catheter System

Two products from Prescient Medical -- the vProtect(TM) Luminal Shield and the vPredict(TM) Optical Catheter System -- will be featured at the 3rd Annual Canaccord Adams Cardiovascular Conference. The conference will take place on Tuesday, November 10th in San Francisco, California, and will bring together a select group of med-tech and biotech companies focused on the most important markets in cardiovascular medicine.

9 Nov 2009

Angiotech Pharmaceuticals reports financial results for the third quarter ended September 30, 2009

Angiotech Pharmaceuticals, Inc. today announced its financial results for the third quarter ended September 30, 2009.

9 Nov 2009

Stent News and Research

Further Reading

Boston Scientific's WallFlex Fully Covered Esophageal Stent receives FDA clearance and CE Mark approval

Cardiovascular Systems commences patient enrollment in CALCIUM 360° clinical trial

Medtronic introduces imaging and visualization service for endovascular specialists

Updated clinical guidelines on Effient treatment for ACS patients

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Endologix receives IDE conditional approval from FDA

W. L. Gore to distribute QXMédical's Q50 Stent Graft Balloon Catheter

Atrium Medical presents interim results from its COBEST clinical study at the 2009 VIVA meeting

New, reversible antiplatelet drug not superior than irreversible one in patients undergoing PCI

Incidence of stroke related to coronary angioplasty remain steady over a 15-year period: Mayo Clinic study

Platelet function tests predict heart attacks in patients pre-treated with two anti-clotting medications before coronary stenting

New reversible blood thinner for angioplasty patients not superior over placebo

New reversible oral anti-platelet medication had fewer cardiac events in heart attack patients

Cappella commences evaluation of the Sideguard Coronary Sidebranch Stent & Delivery System

Resources to help understand stroke and carotid artery disease

Catheter-directed therapy: First-line treatment option for massive pulmonary embolism

GORE TAG Thoracic Endoprosthesis receives European CE Mark approval

FDA issues marketing approval for Onset Medical's SoloPath TransFemoral Endovascular Access Catheter

Prescient Medical to showcase its vProtect Luminal Shield and the vPredict Optical Catheter System

Angiotech Pharmaceuticals reports financial results for the third quarter ended September 30, 2009

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Latest News